4//SEC Filing
Schwabe Stefan K.F. 4
Accession 0001104659-20-138671
CIK 0001356576other
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 5:49 PM ET
Size
9.2 KB
Accession
0001104659-20-138671
Insider Transaction Report
Form 4
Schwabe Stefan K.F.
Executive Vice President R&D
Transactions
- Sale
Common Stock
2020-12-21$22.10/sh−46,347$1,024,463→ 2,772 total - Exercise/Conversion
Common Stock
2020-12-21$12.98/sh+46,347$601,584→ 49,119 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-12-21−46,347→ 0 totalExercise: $12.98Exp: 2026-03-01→ Common Stock (46,347 underlying)
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.2500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vests in four equal annual installments beginning on March 1, 2017.
Documents
Issuer
SUPERNUS PHARMACEUTICALS, INC.
CIK 0001356576
Entity typeother
Related Parties
1- filerCIK 0001557657
Filing Metadata
- Form type
- 4
- Filed
- Dec 21, 7:00 PM ET
- Accepted
- Dec 22, 5:49 PM ET
- Size
- 9.2 KB